New cocktail of drugs hopes to tackle tough breast cancer

NCT ID NCT07601178

Recruiting now Disease control Sponsor: Jiangsu Cancer Institute & Hospital Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase II trial is testing a combination of three drugs—QL1706 (an immunotherapy), anlotinib (a targeted therapy), and nab-paclitaxel (chemotherapy)—as a first treatment for advanced triple-negative breast cancer. The study will enroll 34 women and aims to see if the combo can delay cancer growth. Treatment continues until the disease worsens or side effects become too severe.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: QL1706 (iparomlimab and tuvonralimab), anlotinib hydrochloride, and nab-paclitaxel
What this could lead to: If successful, this combination could offer a new first-line treatment option for advanced triple-negative breast cancer, potentially improving how long the disease is controlled.
What could go wrong: This is a small, early-phase (Phase 2) study with only 34 participants and no comparison group. The combination may cause significant side effects, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED TRIPLE-NEGATIVE BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TNBC - TRIPLE-NEGATIVE BREAST CANCER

Contacts and locations

Locations

Jiangsu Cancer Hospital
RECRUITING

Nanjing, Jiangsu, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.